Cargando…
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581512/ https://www.ncbi.nlm.nih.gov/pubmed/28622427 http://dx.doi.org/10.1111/cas.13301 |
_version_ | 1783261064366915584 |
---|---|
author | Yutani, Shigeru Shirahama, Takahisa Muroya, Daisuke Matsueda, Satoko Yamaguchi, Rin Morita, Michi Shichijo, Shigeki Yamada, Akira Sasada, Tetsuro Itoh, Kyogo |
author_facet | Yutani, Shigeru Shirahama, Takahisa Muroya, Daisuke Matsueda, Satoko Yamaguchi, Rin Morita, Michi Shichijo, Shigeki Yamada, Akira Sasada, Tetsuro Itoh, Kyogo |
author_sort | Yutani, Shigeru |
collection | PubMed |
description | Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC, in which the peptides were selected from 31 peptide candidates based on the pre‐existing immunity. Twenty‐six HCC patients refractory to locoregional therapies (cohort 1) and 30 patients refractory to both locoregional and systemic therapies (cohort 2) were entered into the study. There were no severe adverse events related to PPV except for one injection site reaction. At the end of the first cycle of six vaccinations, successful CTL or IgG boosting was observed in 57% or 46% of patients in cohort 1 and in 54% or 52% of patients in cohort 2, respectively. Successful IgG boosting at the end of the second cycle was observed in the majority of patients tested. Median overall survival was 18.7 months (95% confidence interval, 12.2–22.5 months) in cohort 1, and 8.5 months (95% confidence interval, 5.9–12.2 months) in cohort 2. Based on the higher rates of immune boosting and the safety profile of PPV, further clinical studies of PPV would be warranted for patients with HCC refractory to not only locoregional therapy but also both locoregional and systemic therapies. The protocol of this study was registered with the UMIN Clinical Trials Registry (UMIN000001882 and UMIN000003590). |
format | Online Article Text |
id | pubmed-5581512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55815122017-09-06 Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies Yutani, Shigeru Shirahama, Takahisa Muroya, Daisuke Matsueda, Satoko Yamaguchi, Rin Morita, Michi Shichijo, Shigeki Yamada, Akira Sasada, Tetsuro Itoh, Kyogo Cancer Sci Original Articles Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC, in which the peptides were selected from 31 peptide candidates based on the pre‐existing immunity. Twenty‐six HCC patients refractory to locoregional therapies (cohort 1) and 30 patients refractory to both locoregional and systemic therapies (cohort 2) were entered into the study. There were no severe adverse events related to PPV except for one injection site reaction. At the end of the first cycle of six vaccinations, successful CTL or IgG boosting was observed in 57% or 46% of patients in cohort 1 and in 54% or 52% of patients in cohort 2, respectively. Successful IgG boosting at the end of the second cycle was observed in the majority of patients tested. Median overall survival was 18.7 months (95% confidence interval, 12.2–22.5 months) in cohort 1, and 8.5 months (95% confidence interval, 5.9–12.2 months) in cohort 2. Based on the higher rates of immune boosting and the safety profile of PPV, further clinical studies of PPV would be warranted for patients with HCC refractory to not only locoregional therapy but also both locoregional and systemic therapies. The protocol of this study was registered with the UMIN Clinical Trials Registry (UMIN000001882 and UMIN000003590). John Wiley and Sons Inc. 2017-07-23 2017-09 /pmc/articles/PMC5581512/ /pubmed/28622427 http://dx.doi.org/10.1111/cas.13301 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Yutani, Shigeru Shirahama, Takahisa Muroya, Daisuke Matsueda, Satoko Yamaguchi, Rin Morita, Michi Shichijo, Shigeki Yamada, Akira Sasada, Tetsuro Itoh, Kyogo Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
title | Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
title_full | Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
title_fullStr | Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
title_full_unstemmed | Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
title_short | Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
title_sort | feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581512/ https://www.ncbi.nlm.nih.gov/pubmed/28622427 http://dx.doi.org/10.1111/cas.13301 |
work_keys_str_mv | AT yutanishigeru feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT shirahamatakahisa feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT muroyadaisuke feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT matsuedasatoko feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT yamaguchirin feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT moritamichi feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT shichijoshigeki feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT yamadaakira feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT sasadatetsuro feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies AT itohkyogo feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies |